PROTHENA CORP. PLC DL-,01/ IE00B91XRN20 /
2024-03-28 4:45:22 PM | Chg. -0.200 | Volume | Bid4:45:22 PM | Ask4:45:22 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
22.800EUR | -0.87% | - Turnover: - |
22.800Bid Size: - | 23.000Ask Size: - | 858.11 mill.EUR | - | - |
GlobeNewswire
2022-03-28
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under ...
GlobeNewswire
2022-03-16
Prothena Presents New Data for Alzheimer’s and Parkinson’s Disease Programs at AD/PD 2022
GlobeNewswire
2022-02-17
Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidanc...
GlobeNewswire
2022-02-10
Prothena to Report Fourth Quarter and Full Year 2021 Financial Results and Host Webcast Conference C...
GlobeNewswire
2021-11-04
Prothena Reports Third Quarter 2021 Financial Results and Business Highlights
GlobeNewswire
2021-08-05
Prothena Reports Second Quarter 2021 Financial Results and Business Highlights
GlobeNewswire
2021-07-26
Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association Internat...
GlobeNewswire
2021-07-20
Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association...
GlobeNewswire
2021-07-12
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
GlobeNewswire
2021-06-24
Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global N...
GlobeNewswire
2021-06-10
Prothena to Participate in JMP Securities Life Sciences Conference on June 16
GlobeNewswire
2021-05-20
Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors
GlobeNewswire
2021-05-11
Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&...